Amneal Pharmaceuticals Inc (NAS:AMRX) Stock News, Headlines & Updates
Amneal Pharmaceuticals Inc Stock News from GuruFocus
- 1
Aug 20, 2024
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Business Wire • 11:00am
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Business Wire • 8:00am
Aug 17, 2024
Insider Sale at Amneal Pharmaceuticals Inc (AMRX) by Executive Vice President Andrew Boyer
GuruFocus Research • 9:38pm
Insider Sale at Amneal Pharmaceuticals Inc (AMRX): Executive Vice President Nikita Shah Sells 100,000 Shares
GuruFocus Research • 9:38pm
Aug 09, 2024
Amneal Reports Second Quarter 2024 Financial Results
Business Wire • 6:00am
Aug 07, 2024
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson's Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
Business Wire • 4:01pm
Jul 29, 2024
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
Business Wire • 4:00pm
Jul 11, 2024
Amneal to Report Second Quarter 2024 Results on August 9, 2024
Business Wire • 4:00pm
Jul 09, 2024
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
Business Wire • 4:00pm
Jul 01, 2024
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
Business Wire • 8:00am
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
Business Wire • 8:00am
Jun 28, 2024
Amneal Releases 2023 Environmental, Social and Governance Report
Business Wire • 8:00am
Jun 05, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news